Proteomics

Dataset Information

0

Proteomics of Human Hepatoma Huh-7 Cells Treated by Three Multi-RTK Inhibitors


ABSTRACT: Sorafenib, lenvatinib and regorafenib, the multi-RTK inhibitors with potent anti-angiogenesis effects, are currently therapeutic drugs generally recommended for the patients with advanced hepatocellular carcinoma (HCC). To date, however, there have been no published studies on the mechanism underling differential effects of the three drugs on HCC cell proliferation, and the proteomic analysis in HCC cell lines treated by regorafenib or lenvatinib.The present project for the first time performed a direct comparison of their pharmacological interventions for influencing whole cell proteomics using tandem mass tag-based peptide-labeling technique.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hepatocyte

SUBMITTER: Dezhi Kong  

LAB HEAD: Dezhi Kong

PROVIDER: PXD034073 | Pride | 2022-10-13

REPOSITORIES: Pride

altmetric image

Publications

Cell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors.

Ren Xuejiao X   Zhang Qingning Q   Guo Wenyan W   Wang Lan L   Wu Tao T   Zhang Wei W   Liu Ming M   Kong Dezhi D  

Frontiers in pharmacology 20220822


Sorafenib, lenvatinib and regorafenib, the multi-RTK inhibitors with potent anti-angiogenesis effects, are currently therapeutic drugs generally recommended for the patients with advanced hepatocellular carcinoma (HCC). To date, however, there have been no published studies on the mechanism underling differential effects of the three drugs on HCC cell proliferation, and the proteomic analysis in HCC cell lines treated by regorafenib or lenvatinib. The present study for the first time performed a  ...[more]

Similar Datasets

2022-10-14 | PXD035823 | Pride
2007-03-31 | E-MEXP-943 | biostudies-arrayexpress
2021-06-28 | PXD023859 | Pride
2017-03-27 | PXD005953 | Pride
2014-02-17 | PXD000682 | Pride
2022-10-14 | PXD032300 | Pride
2018-08-06 | PXD008660 | Pride
2011-01-10 | E-GEOD-22916 | biostudies-arrayexpress
2019-03-01 | PXD008373 | Pride
2011-06-10 | E-GEOD-27501 | biostudies-arrayexpress